MEDVi, a telehealth platform serving more than 100,000 patients, today announced an expanded physician-led program ...

The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation ...

Semaglutide is helping patients achieve weight loss previously achievable only with bariatric surgery. But at what cost?

Adults with type 1 diabetes who used a GLP-1 receptor agonist or other incretin-based drug had lower risk for all-cause ...

The new drugs could become the way forward for medicated weight loss as clinical trials reveal optimistic results ...

FDA moves to strike suicide risk warnings from Saxenda, Wegovy, and Zepbound labels after analysis finds no increased risk.

Research has shown that people who stop taking GLP-1 drugs, such as Ozempic and Wegovy, typically experience weight regain within 2 years.

The removal request is based on a ‘comprehensive review of available data’ that showed no increased risk of suicidal ideation and behavior.